OncoCyte (OCX) Stock Price, News & Analysis

Company Overview

OncoCyte Corporation, a precision diagnostics company, focuses on development and commercialization of proprietary tests in the United States and internationally. The company is developing DetermaIO, a gene expression test that assesses the tumor microenvironment to predict response to immunotherapies; DetermaCNI, a blood-based monitoring tool for monitoring therapeutic efficacy in cancer patients; and VitaGraft, a blood-based solid organ transplantation monitoring test. It also provides testing services for biomarker discovery, assay design and development, clinical trial support, and various biomarker tests. The company has a collaboration agreement with Bio-Rad Laboratories, Inc. (Bio-Rad) to collaborate in the development and the commercialization of research use only and in vitro diagnostics kitted transplant products using Bio-Rad's ddPCR instruments and reagents. OncoCyte Corporation was incorporated in 2009 and is based in Irvine, California.

Key Stats

• Today's Range: N/A
• 50-Day Range: $2.60 to $3.44
• 52-Week Range: N/A
• Volume: 100,514 shs
• Average Volume: 58,260 shs
• Market Capitalization: $90.80 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $6.06
• Consensus Rating: Moderate Buy

OncoCyte Stock Analysis - MarketRank™

OncoCyte scored higher than 24% of companies evaluated by MarketBeat, and ranked 839th out of 936 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.4 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

OncoCyte has received a consensus rating of Moderate Buy. The company's average rating score is 2.75, and is based on 3 buy ratings, 1 hold rating, and no sell ratings.

Amount of Analyst Coverage

OncoCyte has only been the subject of 3 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for OncoCyte are expected to grow in the coming year, from ($2.57) to ($1.40) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of OncoCyte is -0.90, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of OncoCyte is -0.90, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Short Interest

• Score: N/A
• Short Interest Level: N/A

Short Interest

There is no current short interest data available for OCX.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

OncoCyte does not currently pay a dividend.

Dividend Growth

OncoCyte does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Short Interest

There is no current short interest data available for OCX.

News and Social Media

• Score: 0.0 / 5
• News Sentiment: N/A

News Coverage This Week

MarketBeat has tracked 1 news article for OncoCyte this week, compared to 1 article on an average week.

Search Interest

Only 1 people have searched for OCX on MarketBeat in the last 30 days. This is a decrease of -67% compared to the previous 30 days.

Company Ownership

• Score: 0.8 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, OncoCyte insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 2.05% of the stock of OncoCyte is held by insiders.

Percentage Held by Institutions

55.35% of the stock of OncoCyte is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

OCX Stock Analysis - Frequently Asked Questions

How were OncoCyte's earnings last quarter?

OncoCyte Corporation (NASDAQ:OCX) announced its quarterly earnings data on Monday, May, 12th. The company reported ($0.26) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.24) by $0.02. The business earned $2.14 million during the quarter, compared to the consensus estimate of $0.13 million. OncoCyte had a negative net margin of 1,516.06% and a negative trailing twelve-month return on equity of 215.59%.
Read the conference call transcript.

When did OncoCyte's stock split?

Shares of OncoCyte reverse split on Tuesday, July 25th 2023.The 1-20 reverse split was announced on Tuesday, July 25th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, July 25th 2023. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split.

Who are OncoCyte's major shareholders?

OncoCyte's top institutional investors include Defender Capital LLC. (0.12%). Insiders that own company stock include Broadwood Partners, LP, Pura Vida Investments, Llc, Andrea S James, Andrew Arno, Alfred D Kingsley, Ronald Asbury Andrews, Andrew J Last and Josh Riggs.
View institutional ownership trends.

What other stocks do shareholders of OncoCyte own?

Based on aggregate information from My MarketBeat watchlists, some other companies that OncoCyte investors own include Alibaba Group (BABA), Meta Platforms (META), Fulcrum Therapeutics (FULC), VBI Vaccines (VBIV), Sorrento Therapeutics (SRNE), CymaBay Therapeutics (CBAY) and Ford Motor (F).

Company Calendar

• Last Earnings: 5/12/2025
• Today: 7/27/2025
• Next Earnings (Estimated): 8/06/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Medical Services
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:OCX
• CIK: 1642380
• Web: oncocyte.com
• Phone: (949) 409-7600
• Fax: 510-521-3389
• Employees: 120
• Year Founded: N/A

Price Target and Rating

• Average Price Target for OncoCyte: $6.06
• High Price Target: $8.00
• Low Price Target: $4.00
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.75
• Research Coverage: 4 Analysts

Profitability

• EPS (Trailing Twelve Months): ($3.53)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$60.66 million
• Net Margins: -1,516.06%
• Pretax Margin: -1,514.57%
• Return on Equity: -215.59%
• Return on Assets: -27.23%

Debt

• Debt-to-Equity Ratio: 0.20
• Current Ratio: 3.74
• Quick Ratio: 3.70

Sales & Book Value

• Annual Sales: $3.84 million
• Price / Sales: 0.00
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($0.70) per share
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 28,599,000
• Free Float: 28,013,000
• Market Cap: $90.80 million
• Optionable: No Data
• Beta: 0.97